JeremyPFeldmanMD

Pulmonology • Phoenix, AZ

Critical Care Medicine, Interventional Pulmonology, Pleural Disease

Founder JPF Advisors Co-Founder Inspire Pulmonary Media

Join to view full profile

Dr. Feldman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Feldman's full profile

Already have an account?

Office
3330 N 2nd St
Suite 300
Phoenix, AZ 85012
Phone+1 602-274-7195

Fax+1 602-274-7097
Is this information wrong?

Summary

I have dedicated the past 20 years to pulmonary vascular disease and advanced lung disease.

I have created educational websites for pulmonary hypertension (pulmonaryhypertensionRN.com) and pulmonary fibrosis (pulmonaryfibrosisMD.com)

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2003 - 2004
Brigham and Women's HospitalResidency, Internal Medicine, 1998 - 2001
University of California San Diego School of MedicineClass of 1998

Certifications & Licensure

AZ State Medical License 2004 - 2025
OR State Medical License 2021 - 2025
CA State Medical License 2001 - 2024
MA State Medical License 2000 - 2004
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. Start of enrollment: 2011 Mar 01
Completed
Phase 2
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies Start of enrollment: 2010 Dec 01
Completed
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy Start of enrollment: 2012 Jun 26
Completed
Phase 3
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension Start of enrollment: 2013 Sep 11
Completed
Phase 3
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
Terminated
Phase 2
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT Start of enrollment: 2014 May 31
Completed
Phase 2
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER Start of enrollment: 2017 Apr 18
Terminated
Phase 3
Pulmonary Hypertension Association Registry Start of enrollment: 2015 Oct 01
Recruiting
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2) Start of enrollment: 2021 Mar 15
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

10 citations
Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.
Aaron Waxman, Ricardo Restrepo-Jaramillo, Thenappan Thenappan, Peter Engel, Abubakr Bajwa, Ashwin Ravichandran, Jeremy Feldman, Amy Hajari Case, Rahul G Argula, Victor...> ;The European Respiratory Journal. 2023 Jun 1
6 citations
AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study.
Hunter Gillies, Ralph Niven, Benjamin T Dake, Murali M Chakinala, Jeremy P Feldman, Nicholas S Hill, Marius M Hoeper, Marc Humbert, Vallerie V McLaughlin, Martin Kankam> ;ERJ Open Research. 2023 Mar 1
6 citations
Pulmonary artery compliance in different forms of pulmonary hypertension.
Amber McCormick, Amita Krishnan, David Badesch, Raymond L Benza, Todd M Bull, Teresa De Marco, Jeremy Feldman, Anna R Hemnes, Russel Hirsch, Evelyn Horn, Jaime Kennedy...> ;Heart. 2023 Jun 26
Erratum: Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: An analysis of the Pulmonary Hypert...
Hilary M DuBrock, Charles D Burger, Sonja D Bartolome, Jeremy P Feldman, David D Ivy, Erika B Rosenzweig, Jeffrey S Sager, Kenneth W Presberg, Stephen C Mathai, Matthe...> ;Pulmonary Circulation. 2022 Oct 1
35 citations
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
Marc Humbert, Vallerie McLaughlin, J Simon R Gibbs, Mardi Gomberg-Maitland, Marius M Hoeper, Ioana R Preston, Rogerio Souza, Aaron B Waxman, Hossein-Ardeschir Ghofrani...> ;The European Respiratory Journal. 2023 Jan 1
2 citations
INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH).
Nicholas S Hill, Jeremy P Feldman, Sandeep Sahay, Raymond L Benza, Ioana R Preston, David Badesch, Robert P Frantz, Savan Patel, Ashley Galloway, Todd M Bull> ;Pulmonary Circulation. 2022 Jul 1
3 citations
Prediction of patient outcomes through social determinants of health: The Pulmonary Hypertension Association Registry (PHAR) evaluation.
Dan Grinnan, Le Kang, Christine DeWilde, David Badesch, Raymond Benza, Todd Bull, Murali Chakinala, Teresa DeMarco, Jeremy Feldman, Hubert J Ford, James Klinger, John ...> ;Pulmonary Circulation. 2022 Jul 1
1 citations
HIV-associated Pulmonary Arterial Hypertension: A Report from the Pulmonary Hypertension Association Registry.
Nicholas A Kolaitis, Matthew Lammi, Sula Mazimba, Jeremy Feldman, Wes McConnell, Jeffrey S Sager, Abhijit A Raval, Marc A Simon, Teresa De Marco> ;American Journal of Respiratory and Critical Care Medicine. 2022 May 1
11 citations
A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2).
Howard M Lazarus, Jill Denning, Stephen Wring, Michelle Palacios, Sidra Hoffman, Katelyn Crizer, Watiri Kamau-Kelley, William Symonds, Jeremy Feldman> ;Pulmonary Circulation. 2022 Apr 1
4 citations
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat.
Franck F Rahaghi, Vijay P Balasubramanian, Robert C Bourge, Charles D Burger, Murali M Chakinala, Michael S Eggert, Jean M Elwing, Jeremy Feldman, Christopher King, Ja...> ;Pulmonary Circulation. 2022 Apr 1
15 citations
A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen.
Christopher S. King, Kevin R. Flaherty, Marilyn K. Glassberg, Lisa Lancaster, Ganesh Raghu, Jeffrey J. Swigris, Rahul G. Argula, Rosemarie A Dudenhofer, Neil A. Etting...> ;Annals of the American Thoracic Society. 2021 Oct 22
2 citations
Health-related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis fro...
Jasleen Minhas, Sai Prasanna Narasimmal, Todd M. Bull, Teresa De Marco, J.W. McConnell, Matthew R. Lammi, Thenappan Thenappan, Jeremy Feldman, Jeffrey Sager, David B. ...> ;Pulmonary Circulation. 2021 Oct 14
70 citations
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Kelly Chin, Olivier Sitbon, Martin Doelberg, Jeremy Feldman, J. Simon R. Gibbs, Ekkehard Grünig, Marius M. Hoeper, Nicolas Martin, Stephen C. Mathai, Vallerie V. McLau...> ;Journal of the American College of Cardiology. 2021 Oct 5
12 citations
Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial.
Stephan Rosenkranz, Jeremy Feldman, Vallerie V. McLaughlin, Franz Rischard, Tobias J. Lange, R. James White, Andrew J. Peacock, Felix Gerhardt, Ramin Ebrahimi, Gabriel...> ;The Lancet. Respiratory Medicine. 2021 Aug 20
12 citations
Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension As...
Hilary M. DuBrock, Charles D. Burger, Sonja Bartolome, Jeremy Feldman, D. Dunbar Ivy, Erika B. Rosenzweig, J.S. Sager, Kenneth W. Presberg, Stephen C. Mathai, Matthew ...> ;Pulmonary Circulation. 2021 Jun 6
1 citations
Comparison of shock reversal with high or low dose hydrocortisone in intensive care unit patients with septic shock: A retrospective cohort study.
Sophia Bonnin, John J. Radosevich, Yong Gu Lee, Jeremy Feldman, Jeffrey F. Barletta> ;Journal of Critical Care. 2021 Apr 1
152 citations
Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
Marc Humbert, Vallerie V. McLaughlin, J. Simon R. Gibbs, Mardi Gomberg-Maitland, Marius M. Hoeper, Ioana R. Preston, Rogério Souza, Aaron Waxman, Pilar Escribano Subía...> ;The New England Journal of Medicine. 2021 Apr 1
1 citations
An expert panel delphi consensus statement on patient selection and management for transitioning between oral and inhaled treprostinil.
Franck Rahaghi, Roblee P Allen, Vijay Balasubramanian, Murali M. Chakinala, Jean M. Elwing, Jeremy Feldman, Peter J. Leary, Franz Rischard, Zeenat Safdar, Namita Sood,...> ;Pulmonary Pharmacology & Therapeutics. 2021 Feb 1
8 citations
Obesity in pulmonary arterial hypertension the pulmonary hypertension association registry
Jeff Min, Rui Feng, David B. Badesch, Erika Berman-Rosenzweig, Charles D. Burger, Murali M. Chakinala, Teresa De Marco, Jeremy Feldman, Anna R. Hemnes, Evelyn M. Horn,...> ;Annals of the American Thoracic Society. 2021 Feb 1
206 citations
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
Aaron B. Waxman, Ricardo Restrepo-Jaramillo, Thenappan Thenappan, Ashwin Ravichandran, Peter A. Engel, Abubakr Bajwa, Roblee P Allen, Jeremy Feldman, Rahul G. Argula, ...> ;The New England Journal of Medicine. 2021 Jan 28
1 citations
Implantable system for treprostinil and lung transplantation: case series from delivery for pulmonary arterial hypertension study.
Jeremy Feldman, Mardi Gomberg-Maitland, Shelley M. Shapiro, Amy A Lautenbach, Marty Morris, Jeffrey A. Murphy, Aaron B. Waxman, Robert C. Bourge> ;Pulmonary Circulation. 2021 Jan 1
1 citations
Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics:
R. James White, Keyur Parikh, Roblee P Allen, Jeremy Feldman, Carlos Jerjez-Sanchez, Lei Pan, Anne Keogh, C. Dario Vizza, Shelley Shapiro, Kathryn Gordon, Meredith Bro...> ;Pulmonary Circulation. 2020 Dec 8
9 citations
Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry.
Nicholas A. Kolaitis, Roham T. Zamanian, Vinicio A. de Jesus Perez, David B. Badesch, Raymond L. Benza, Charles D. Burger, Murali M. Chakinala, Jean M. Elwing, Jeremy ...> ;Annals of the American Thoracic Society. 2021 Apr 1
3 citations
Transitioning From Intravenous to Subcutaneous Prostacyclin Therapy in Neonates With Severe Pulmonary Hypertension.
Meghan N Turbenson, John J. Radosevich, Vinit Manuel, Jeremy Feldman> ;The Journal of Pediatric Pharmacology and Therapeutics. 2020 Sep 1
1 citations
Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
John J. Radosevich, Audra DeChristopher, Maykel Irandost, Jade Fann, Jeremy Feldman> ;American Journal of Health-System Pharmacy. 2020 Jul 23
Join now to see all

Press Mentions

Phase 3 INOpulse Trial Enrolls First Patient at Risk of PF-Associated PHDecember 4th, 2020
First Patient Enrolled in Phase 3 REBUILD Trial of INOpulseDecember 4th, 2020
New Pulmonary Hypertension Association Accreditation Program and Registry Giving New Understanding to Specialists Caring for People Living with Pulmonary HypertensionFebruary 3rd, 2017